Skip to main content

Advertisement

Log in

Peptide radiopharmaceuticals for diagnosis and therapy

  • Occasional Survey
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

An Erratum to this article was published on 26 September 2001

Abstract.

Radiolabelled peptides are an emerging class of radiopharmaceuticals that share chemical and biological properties. From the chemical point of view they have a poly-amino acid structure varying from 3 to more that 200 amino acids, and they are labelled with different isotopes directly or by a linker. Biologically, they bind to specific cell membrane receptors, thus providing in vivo histopathological information for diagnostic purposes, therapy follow-up or targeted radiotherapy. This paper reviews most of the radiolabelled peptides that have been tested in animals and humans in the fields of oncology, neurology, cardiology, inflammation/infection, atherosclerosis and thrombosis. A new classification is also proposed for peptides targeting tumour cells based on the biological function of target receptors. These tailored radiopharmaceuticals are the basis of the new era of "molecular nuclear medicine".

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Electronic Publication

An erratum to this article is available at http://dx.doi.org/10.1007/s00259-001-0663-7.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Signore, .A., Annovazzi, .A., Chianelli, .M. et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 28, 1555–1565 (2001). https://doi.org/10.1007/s002590100583

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002590100583

Navigation